256 related articles for article (PubMed ID: 20799994)
1. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro.
Zhao Q; Zhang H; Li Y; Liu J; Hu X; Fan L
J Exp Clin Cancer Res; 2010 Aug; 29(1):118. PubMed ID: 20799994
[TBL] [Abstract][Full Text] [Related]
2. Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines.
Liu Z; Qiu M; Tang QL; Liu M; Lang N; Bi F
Chin J Cancer; 2010 Jul; 29(7):661-7. PubMed ID: 20591218
[TBL] [Abstract][Full Text] [Related]
3. Polyene phosphatidylcholine overcomes oxaliplatin resistance in human gastric cancer BGC823 cells.
Zhang H; Song H; Yuan R; Zhang X; Yu H; Zhao Y; Jiang T
Biochem Biophys Res Commun; 2018 Feb; 497(1):108-114. PubMed ID: 29421658
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-15-transferred cytokine-induced killer cells elevated anti-tumor activity in a gastric tumor-bearing nude mice model.
Peng Z; Liang W; Li Z; Xu Y; Chen L
Cell Biol Int; 2016 Feb; 40(2):204-13. PubMed ID: 26503216
[TBL] [Abstract][Full Text] [Related]
5. [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98].
Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):566-570. PubMed ID: 28534337
[TBL] [Abstract][Full Text] [Related]
6. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
[TBL] [Abstract][Full Text] [Related]
7. Txr1: an important factor in oxaliplatin resistance in gastric cancer.
Bi J; Bai Z; Ma X; Song J; Guo Y; Zhao J; Yi X; Han S; Zhang Z
Med Oncol; 2014 Feb; 31(2):807. PubMed ID: 24362794
[TBL] [Abstract][Full Text] [Related]
8. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
[TBL] [Abstract][Full Text] [Related]
9. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells.
Kim YJ; Lim J; Kang JS; Kim HM; Lee HK; Ryu HS; Kim JY; Hong JT; Kim Y; Han SB
Arch Pharm Res; 2010 Nov; 33(11):1789-95. PubMed ID: 21116782
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
14. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
[TBL] [Abstract][Full Text] [Related]
15. EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells.
Wen Q; Chen Z; Chen Z; Chen J; Wang R; Huang C; Yuan W
Oncotarget; 2017 Jul; 8(29):47998-48011. PubMed ID: 28624791
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
17. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients.
Jiang JT; Shen YP; Wu CP; Zhu YB; Wei WX; Chen LJ; Zheng X; Sun J; Lu BF; Zhang XG
World J Gastroenterol; 2010 Dec; 16(48):6155-62. PubMed ID: 21182234
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361.
Wu X; Zheng Y; Han B; Dong X
Biomed Pharmacother; 2018 Mar; 99():832-838. PubMed ID: 29710482
[TBL] [Abstract][Full Text] [Related]
19. Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.
Gammaitoni L; Giraudo L; Macagno M; Leuci V; Mesiano G; Rotolo R; Sassi F; Sanlorenzo M; Zaccagna A; Pisacane A; Senetta R; Cangemi M; Cattaneo G; Martin V; Coha V; Gallo S; Pignochino Y; Sapino A; Grignani G; Carnevale-Schianca F; Aglietta M; Sangiolo D
Clin Cancer Res; 2017 May; 23(9):2277-2288. PubMed ID: 27815354
[No Abstract] [Full Text] [Related]
20. Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells.
Zhang P; Shi L; Zhang T; Hong L; He W; Cao P; Shen X; Zheng P; Xia Y; Zou P
Cell Oncol (Dordr); 2019 Dec; 42(6):847-860. PubMed ID: 31493144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
